About

About Image

      About

      Bone Biologics is a publicly traded company based in Boston, MA and is focused on developing and marketing orthobiologic products. Our proprietary platform technology is NELL-1, a recombinant human protein growth factor that is essential for normal bone development. Our lead product is a NELL-1 based bone graft substitute for spine fusion, targeting the rapidly growing orthobiologics market. Our goal is to offer patients superior safety with uncompromising efficacy relative to existing technologies. NELL-1  provides specific targeted regulation over bone regeneration in the presence of targeted osteogenic cells, as both demonstrated in the lab and through the use of animal testing, unlike any other current therapy. It has been shown not to form bone when applied to non-osteogenic cells such as myoblasts (a type of embryonic progenitor cell that differentiates to give rise to muscle cells) nor does it induce adipogenesis (the formation of fat that can occur within the bone matrix often exhibited as cysts) that results in weaker bone.

      MISSION
      Our mission is to utilize the power of NELL-1 to improve clinical outcomes and reduce total health care delivery costs associated with spinal fusion. Bone Biologics is focused on bone repair and regeneration applications and is committed to exploring additional applications of the NELL-1 technology to enhance bone regeneration and repair in areas where the current options provide suboptimal patient outcomes.

      Leadership

      Leadership Image

          Leadership

          The Bone Biologics leadership team consists of some of the top leaders and innovators of orthobiologics in regenerative medicine. Not only does our leadership provide strategic oversight of the Company, they contribute to the collective advancement of the industry. This leadership is instrumental in fulfilling our mission to improve clinical outcomes and reduce health care delivery costs associated with lumbar spinal fusion.

          Products

          Products Image

              Products

              While Bone Biologics has chosen to focus its initial product development efforts in spinal fusion, we believe that this regenerative medicine technology has potential in the broader fields of bone regeneration and repair including osteoporosis, chondrocytes and applications using mesenchymal stem cells.

               

              Investor Relations

              Investor Relations Image

              Press Releases

              Current Press Releases

              News Archive

              Bone Biologics Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com

              NEW YORK, Sept. 16, 2013 /PRNewswire/ — Bone Biologics today announced its September 12thRetailInvestorConferences.com presentation is now available for on-demand viewing.

              + Read More

              Bone Biologics Announces a Major US Patent Issuance For Its Recombinant Protein Process For the Formation of Cartilage

              THOUSAND OAKS, Calif., Feb. 24 /PRNewswire/ — Bone Biologics, Inc. announced today that it has successfully completed the initial primate trials validating the efficacy of the proprietary bone growth regeneration UCB-1 (NELL-1™) protein in spinal fusion surgery. 100% fusion was obtained in a 3 month period. No cystic lesion was observed. The company is currently preparing Pre-IDE studies.

              + Read More

              Bone Biologics Announces Another Round of Equity and Debt Investment by Musculoskeletal Transplant Foundation and the Addition of Board Member, Mark Spilker

              THOUSAND OAKS, Calif., March 10 /PRNewswire/ — Bone Biologics, Inc. announced today it had received another round of investment for preferred shares from the Musculoskeletal Transplant Foundation (MTF). MTF now owns 51% of Bone Biologics. As part of the financing, MTF also provided a line of credit to fund continuing operations. This financial support continues the investments by MTF that have allowed Bone Biologics, Inc. to progress from research through development of the NELL-1™ protein sequence UCB-1 to the current culmination of:

              + Read More

              Bone Biologics Announces Significant Milestone for Spinal Fusion Surgery Using Recombinant Protein and Demineralized Bone Matrix

              THOUSAND OAKS, Calif., Feb. 24 /PRNewswire/ — Bone Biologics, Inc. announced today that it has successfully completed the initial primate trials validating the efficacy of the proprietary bone growth regeneration UCB-1 (NELL-1™) protein in spinal fusion surgery. 100% fusion was obtained in a 3 month period. No cystic lesion was observed. The company is currently preparing Pre-IDE studies.

              + Read More

              « Newer EntriesOlder Entries »

              Contact

              Contact Image

                  Contact

                  General Inquiries:
                  Chris Martin
                  412.749.9299 x2
                  Chris@AtlasStories.com

                  Investor Inquiries:
                  Mark Collinson
                  714.222.5161
                  mcollinson@compass-ir.com

                  Media Inquiries:
                  Tracy Williams
                  310.824.9000 x22
                  tracy@olmsteadwilliams.com

                  For information regarding our company and/or products, please complete the form below.





                  Your Name (required)

                  Organization

                  Title

                  Email (required)

                  Phone

                  Preferred Means of Reply

                  Your Message

                  Scratch Pad
                  Parent : investor-relations 11